• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

作者信息

Passiglia Francesco, Novello Silvia

机构信息

Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy.

出版信息

Ann Transl Med. 2018 Dec;6(Suppl 2):S120. doi: 10.21037/atm.2018.12.25.

DOI:10.21037/atm.2018.12.25
PMID:30740441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6330599/
Abstract
摘要

相似文献

1
Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?广泛期小细胞肺癌一线免疫治疗：拼图又将添新块？
Ann Transl Med. 2018 Dec;6(Suppl 2):S120. doi: 10.21037/atm.2018.12.25.
2
Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle.免疫抑制检查点Siglec-15：癌症免疫治疗拼图中至关重要的新板块。
Cancer Biol Med. 2019 May;16(2):205-210. doi: 10.20892/j.issn.2095-3941.2018.0141.
3
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?复发性卵巢癌的免疫治疗：是进一步解决问题的方法，还是引人注目的策略？
Expert Opin Biol Ther. 2014 Jan;14(1):103-14. doi: 10.1517/14712598.2014.859671.
4
What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?在免疫治疗时代，放疗对于广泛期小细胞肺癌的作用是什么？
Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S153-S162. doi: 10.21037/tlcr.2019.05.01.
5
A very tiny ancestor. Scientists fill in a piece of the evolutionary puzzle.
Newsweek. 2000 Mar 27;135(13):66.
6
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌的成本效果分析。
Lung Cancer. 2019 Apr;130:1-4. doi: 10.1016/j.lungcan.2019.01.019. Epub 2019 Feb 1.
7
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?成功与失败：我们从近期非小细胞肺癌一线治疗免疫疗法试验中学到了什么？
BMC Med. 2017 Mar 13;15(1):55. doi: 10.1186/s12916-017-0819-3.
8
Where are we going with computer-assisted or robotic cardiac surgery? A piece of the totally endoscopic coronary bypass puzzle.
J Thorac Cardiovasc Surg. 2002 Jun;123(6):1029-30. doi: 10.1067/mtc.2002.124964.
9
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.葡萄牙免疫治疗时代前晚期非小细胞肺癌的真实世界治疗模式和生存结局：来自 I-O Optimise 计划的回顾性分析。
BMC Pulm Med. 2020 Sep 10;20(1):240. doi: 10.1186/s12890-020-01270-z.
10
The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy.癌症干细胞/癌症起始细胞与肿瘤微环境之间的相互作用：免疫疗法有效靶向这些细胞的关键缺失环节。
Cancer Microenviron. 2019 Dec;12(2-3):133-148. doi: 10.1007/s12307-019-00233-1. Epub 2019 Nov 22.

引用本文的文献

1
What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?在免疫治疗时代，放疗对于广泛期小细胞肺癌的作用是什么？
Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S153-S162. doi: 10.21037/tlcr.2019.05.01.
2
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].[肺癌中PD-1/PD-L1检查点抑制剂的研究进展]
Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):369-379. doi: 10.3779/j.issn.1009-3419.2019.06.07.

本文引用的文献

1
NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.NCCN 指南解读：小细胞肺癌，2018 年版 2.0
J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182. doi: 10.6004/jnccn.2018.0079.
2
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.三线纳武利尤单抗单药治疗复发性小细胞肺癌：CheckMate 032。
J Thorac Oncol. 2019 Feb;14(2):237-244. doi: 10.1016/j.jtho.2018.10.003. Epub 2018 Oct 10.
3
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌：欧洲肿瘤内科学会临床实践诊断、治疗及随访指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.
4
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
5
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
6
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).广泛期小细胞肺癌（SCLC）患者维持帕博利珠单抗治疗的 II 期研究。
J Thorac Oncol. 2018 Sep;13(9):1393-1399. doi: 10.1016/j.jtho.2018.05.002. Epub 2018 Jul 17.
7
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.肿瘤突变负担与纳武利尤单抗单药治疗及联合伊匹单抗治疗小细胞肺癌的疗效。
Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3.
8
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
9
ESMO-Magnitude of Clinical Benefit Scale version 1.1.ESMO-临床获益量表 1.1 版
Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310.
10
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.帕博利珠单抗治疗广泛期小细胞肺癌患者：来自 Ib 期 KEYNOTE-028 研究的结果。
J Clin Oncol. 2017 Dec 1;35(34):3823-3829. doi: 10.1200/JCO.2017.72.5069. Epub 2017 Aug 16.